Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
Here’s a look at some of the top COVID-19-related stories for today.
Eli Lilly and Novo Nordisk published their data in The Lancet Diabetes & Endocrinology and presented them at the ADA conference.
The company said it will file a marketing application later this year for the drug under the FDA’s accelerated approval pathway.
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
JOBS
IN THE PRESS